Therapeutic Uses
Antiretroviral / Anti-HIV
Storage Condition
Store at freezer (-20ยฐC) for long term storage
Synonyms
dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-([1,1'-biphenyl]-4,4'-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate-d6
Application Notes
Useful research chemical for a range of applications
Purity by HPLC
Not less than 90%
Hazard Compound
No -Refer MSDS for accurate information
Daclatasvir-d6 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Daclatasvir-d6 usage and description
Daclatasvir D6 is a deuterium-labeled version of Daclatasvir, which is a direct-acting antiviral medication used for the treatment of chronic hepatitis C virus (HCV) infection. Daclatasvir D6 is a potent, selective, and orally active NS5A inhibitor, which means it prevents the replication of HCV by blocking the action of the non-structural protein 5A (NS5A).
The usage of Daclatasvir D6 is similar to that of Daclatasvir, and it is typically administered in combination with other antiviral agents such as sofosbuvir. The treatment regimen and dosage may vary depending on the patient's genotype and medical history. The medication is generally well-tolerated, with few side effects reported.
Chemically, Daclatasvir D6 is an isotopically labeled analog of Daclatasvir, with six deuterium atoms replacing six hydrogen atoms in the molecular structure. This labeling enhances the drug's stability and helps improve its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion.
In conclusion, Daclatasvir D6 is a useful tool for researchers and medical professionals in studying the pharmacokinetics and metabolism of Daclatasvir. Its usage in treating chronic HCV infection is similar to that of the non-labeled version and offers an effective and safe treatment option for patients.